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Introduction
Osteoporosis is a common disease where bone mass is 
reduced, leading to an increased risk of bone fracture. Half of 
Caucasian women and a fifth of men experience osteoporosis-
related bone fracture in the course of lifetime [1]. Treatment 
of osteoporosis-related fracture causes enormous socioeco-
nomic burden, costing nearly $17 billion in 2005 in the U.S.; it 
is expected to double or triple in the next four decades due to 
rapidly aging population [2]. 
Osteoporosis is caused by an imbalance of osteoblastic 
bone formation and osteoclastic bone resorption. Thus, anti-
osteoporosis medications aim to reduce the risk of bone frac-
ture either by increasing bone formation or suppressing bone 
resorption. Currently, four classes of anti-resorptive agents 
and one class of anabolic agent are approved by the U.S. Food 
and Drug Administration for the treatment of osteoporosis 
(Table 1). However, these medications have failed to increase 
bone formation or decrease bone resorption in isolation due to 
the closed coupling of osteoblasts and osteoclasts whereby 
changes in differentiation or activity of one cell type directly af-
fect the other [3]. This phenomenon not only limits the efficacy 
of anti-osteoporosis drugs, but also is associated with signifi-
cant side effects [4]. In this article, we review the biological 
aspects of anti-osteoporosis drugs, focusing on the mecha-
nisms of action and osteoblast–osteoclast coupling. 
Anti-resorptive Drugs
1. Bisphosphonates
Bisphosphonates (BPs) are the most common class of medi-
cations for the treatment of osteoporosis. They are analogues 
of pyrophosphate and become highly concentrated in mineral-
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ized tissues because the oxygen atoms in the phosphonate 
groups have a high affinity for divalent cations such as calcium. 
This leads to the osteoclast-specific effect of BPs, since they 
are released from bone tissue by osteoclastic bone resorption 
and internalized by adjacent osteoclasts. Although the mecha-
nism by which BPs inhibit osteoclastic bone resorption is not 
fully understood, they block farnesyl diphosphate synthase 
(FPPS) in the mevalonate pathway [5]. Disruption of FPPS pre-
vents formation of farnesol and geranylgeraniol for prenylation 
of multiple proteins, including small guanosine triphosphatases 
(GTPases) [6], that are critically involved in the differentiation 
and survival of osteoclasts [7]. The anti-osteoclastogenic ef-
fect of BPs are rescued by the addition of geranylgeraniol, but 
not farnesol, in vitro [8], supporting the view that interference 
with protein prenylation may be the underlying mechanism 
of BP action. Recently, cholesterol has been found to be the 
endogenous ligand for the estrogen-related receptor alpha 
(ERRα), originally known as an orphan nuclear receptor [9]. 
BPs exert their anti-osteoclastogenic effect by blocking the 
mevalonate pathway and decreasing intracellular cholesterol 
levels, leading to decreased activation of ERRα. Consequently, 
hypercholesterolemia-induced bone loss and the osteoprotec-
tive effect of BPs are abolished in ERRα knockout mice [9].
BPs effectively reduce the risk of vertebral, non-vertebral, 
and hip fractures by suppression of osteoclastic bone resorp-
tion [10]. Although there is some in vitro evidence that BPs 
may have an anabolic effect on osteoblasts [11], BPs decrease 
not only osteoclastic bone resorption but also osteoblastic dif-
ferentiation in vivo [12]. This is primarily due to the coupling of 
osteoblasts and osteoclasts; inhibition of osteoclast differen-
tiation and bone resorption decrease production and/or release 
of osteoblast-stimulating osteoclast-derived growth factors, 
such as Wnt10a and sphingosine-1-phosphate, and matrix-
derived growth factors, such as transforming growth factor-β1 
and insulin-like growth factor-1 [4,13]. The excessively low 
bone turnover caused by BPs has been associated with some 
rare but serious side effects, such as atypical femoral shaft 
fracture and medication-related osteonecrosis of the jaw 
(MRONJ), although the mechanisms of pathogenesis of these 
are still poorly understood [14]. 
2.  Receptor activator of nuclear factor kappa-B ligand 
antibody (Denosumab)
Denosumab is a fully humanized monoclonal antibody that 
targets receptor activator of nuclear factor kappa-B ligand 
(RANKL) [15]. RANKL, which belongs to the tumor necrosis 
factor family, binds to the RANK (receptor activator of nuclear 
factor kappa-B) receptor on myeloid lineage cells and this 
binding interaction is a key step for the differentiation of osteo-
clast precursors into mature osteoclasts. Denosumab binds to 
RANKL and prevents RANKL from binding to RANK, inhibiting 
differentiation, activation, and survival of osteoclasts. 
Denosumab reduces the risk of vertebral, non-vertebral, and 
hip fractures by suppressing bone resorption [16]. Due to os-
teoblast–osteoclast coupling, denosumab also decreases os-
teoblastic bone formation, similarly to BPs, and has also been 
associated with atypical femoral shaft fracture and MRONJ 
[17]. With regard to the MRONJ, however, denosumab has an 
advantage over BPs due to its shorter half-life. BPs are accu-
mulated in bone minerals and slowly released by osteoclastic 
bone resorption, even years after stopping treatment. In con-
trast, denosumab reversibly inhibits RANKL, such that bone 
turnover markers are rapidly recovered within a few months 
after discontinuation [14,18]. Denosumab increases the risk 
of infections such as cellulitis, probably due to the inhibition of 
RANKL in the immune system, although the pathogenesis of 
this is not fully understood [19]. 
3. Hormone replacement therapy: estrogen therapy
Menopause is one of the most important risk factors for 
osteoporosis in middle-aged women [20]. This is because 
estrogen positively regulates bone and mineral homeostasis, 
Table 1. U.S. Food and Drug Administration-approved anti-osteo-
porosis medications (March, 2019)
Class Generic name 
Anti-resorptive reagents




    RANKL antibody Denosumab
    Hormone replacement therapy Estradiol, estropipate, 
conjugated estrogen
    Selective estrogen receptor modulators Raloxifene
Bazedoxifene
Anabolic reagents
    Parathyroid hormone receptor agonist Teriparatide
Abaloparatide
RANKL, receptor activator of nuclear factor kappa-B ligand.
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primarily by suppressing osteoclastic bone resorption [21]. 
Estrogen has both direct and indirect effects on osteoclasts. 
The direct effects of estrogen are clearly demonstrated by 
osteoclast-specific estrogen receptor alpha (ERα) knockout 
mice, which show decreased trabecular bone mass [22,23]. 
Estrogen induces apoptosis of osteoclasts and inhibits RANKL-
induced osteoclast differentiation [21]. Besides the direct ef-
fects, estrogen decreases production of RANKL and increases 
production of osteoprotegrin, a decoy receptor for RANKL, by 
osteoblasts [24,25]. In contrast to the effect on osteoclasts, 
estrogen has minor effects on osteoblastic bone formation. 
Although the estrogen has been found to inhibit apoptosis and 
increase the lifespan of osteoblasts [26], mice in which ERα 
was specifically knocked out in osteoblasts using Col1a1-cre 
showed no discernable bone phenotype. Deletion of ERα in 
osteoblast progenitors using Prx1-cre and Osx1-cre led to de-
creased cortical, but not cancellous, bone mass; however, this 
effect was due to the estrogen-independent function of ERα 
[27]. Overall, estrogen therapy mainly exerts anti-resorptive 
effects, thereby decreasing osteoblastic bone formation due 
to osteoblast–osteoclast coupling, although its effects are less 
profound than the effect of BP or denosumab therapy.
Estrogen is usually used in combination with progesterone to 
reduce the risk of endometrial cancer in unopposed estrogen 
therapy [28]. With or without progesterone, estrogen therapy 
reduces the risk of vertebral, non-vertebral, and hip fractures 
in post-menopausal women [29]. However, estrogen therapy, 
even in combination with progesterone, has unwanted side ef-
fects in other organs besides the bone. The Women’s Health 
Initiative trial, a large study of over 27,000 women sponsored 
by the U.S. government, concluded that the increased risk of 
breast cancer and stroke caused by estrogen therapy exceeded 
its beneficial effects, especially in older patients (over the age 
of 60 at the beginning of treatment) [30,31]. Currently, guide-
lines recommend the use of estrogen therapy for prevention of 
bone loss in women with premature menopause or for women 
with vasomotor symptoms who are younger than 60 years or 
within 10 years of menopause, in the absence of contraindica-
tions [32].
4. Selective estrogen receptor modulators
Selective estrogen receptor modulators (SERMs) are a class 
of compounds that bind to the estrogen receptor (ER) and 
act as an agonist or antagonist depending on the target tis-
sue. Raloxifene and bazedoxifene, for example, are estrogenic 
for the bone and liver, but anti-estrogenic for the breast and 
endometrium (raloxifene is neutral for the endometrium) [33]. 
Thus, they have the beneficial effects of estrogen therapy on 
bone, but may even reduce the risk of invasive breast cancer, 
although they still increase the risk of venous thromboembo-
lism due to anabolic effects on coagulation factors in the liver 
[34]. The tissue-selective agonistic or antagonistic effect of 
SERMs is presumed to be associated with several factors as 
follows: 1) ligand-dependent promotion or inhibition of recruit-
ment of transcriptional coregulators to the SERM-ER complex 
and tissue-specific enrichment of those coregulators; 2) regu-
lation of coactivator stability or activity by SERM; and 3) pref-
erential affinity of SERM to ERα over β and differential tissue 
distribution of these ER isoforms [35].
Both raloxifene and bazedoxifene reduce the risk of vertebral 
fractures, but not non-vertebral or hip fractures [36,37]. Thus, 
these SERMs are recommended for younger postmenopausal 
women, who have low risk of hip fracture, especially for those 
who are concerned about the risk of breast cancer [17].
Anabolic Drugs
1. Parathyroid hormone receptor agonists
Currently, the only class of anabolic drug approved for the 
treatment of osteoporosis is parathyroid hormone (PTH) re-
ceptor agonists, which include teriparatide and abaloparatide. 
Teriparatide is a recombinant protein containing the first 34 
amino acids of human PTH, which retain the essential anabolic 
effect of native PTH. Abaloparatide is a synthetic analogue of 
parathyroid hormone-related protein with 76% homology. Both 
drugs bind to the parathyroid hormone 1 receptor (PTH1R), 
primarily present in the bone and kidney.
The primary physiological function of PTH is to raise the 
plasma calcium concentration in response to low plasma cal-
cium levels by acting primarily on the bone and kidney. Al-
though conflicting results regarding the direct effect of PTH on 
the osteoclasts have been reported, it is now widely accepted 
that PTH binds to PTH1R in osteoblasts and increases RANKL 
expression to indirectly stimulate osteoclastic bone resorption, 
thereby liberating calcium into the plasma [38]. PTH, however, 
also simultaneously increases osteoblastic bone formation by 
promoting osteoblast differentiation and survival. Thus, PTH 
has both catabolic and anabolic effects on bone, and the bal-
ance is determined by the duration for which PTH remains 
available to the PTH1R in osteoblasts. While the continuous 
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elevation of PTH levels in hyperparathyroidism results in in-
creased bone resorption being dominant over increased bone 
resorption and net bone loss, a brief elevation (1 to 3 hours) 
of PTH levels by therapeutic intermittent injection primarily 
stimulates bone formation and increases bone mass [38]. The 
mechanism of this biphasic effect of PTH (continuous vs. in-
termittent) is not fully understood, but longer exposure of os-
teoblasts to PTH seems to be necessary for increasing RANKL 
expression, in contrast to cell-autonomous anabolic effects 
[39].
Both teriparatide and abaloparatide reduce the risk of ver-
tebral and non-vertebral fractures [40,41]. However, the use 
of these drugs is limited to 18 to 24 months for two reasons. 
First, there is a theoretical concern about increased risk of os-
teosarcoma because treatment with PTH for two years greatly 
increased the risk of osteosarcoma in rats [42], although there 
is no evidence that PTH increases the risk of osteosarcoma in 
humans. Second, because of osteoblast–osteoclast coupling, 
the osteoclastic bone resorption slowly begins to increase after 
several months of PTH treatment. During the first 24 months 
of treatment, the rate of bone formation is greater than that of 
bone resorption, making the so-called ‘anabolic window’, but 
eventually the increasing rate bone resorption equals that of 
bone formation and there is no net gain in bone mass [43]. 
Conclusions
Bone fractures from osteoporosis can be life-threatening 
in older people. Current anti-osteoporosis drugs are being 
successfully used to reduce the risk of these fractures. How-
ever, all medications are subject to the effects of osteoblast–
osteoclast coupling, limiting treatment efficacy and safety. 
The recently developed sclerostin antibody, Romosozumab, 
may be the first medication to uncouple the activities of os-
teoblasts and osteoclasts and exert simultaneously anabolic 
and anti-catabolic effects, although there are concerns about 
the increased risk of cardiovascular disease [44]. Future anti-
osteoporosis drugs may target the osteoblast–osteoclast cou-
pling process to develop more effective and safe medications. 
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